ShutterstockWomen with HIV taking antiretroviral combinations containing tenofovir alafenamide (TAF) and a cobicistat-boosted protease inhibitor or integrase inhibitor were more likely to experience numerous physical symptoms of depression than women taking other antiretroviral regimens, the Women’s Interagency HIV Study reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle.
The study investigators say their findings suggest that doctors need to look at drug combinations rather than individual antiretrovirals when considering whether HIV medication might be causing or contributing to the physical symptoms of depression.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.